Indications

Our focus on eating disorders, particularly Anorexia Nervosa, is driven by the urgent need to address the significant challenges and unmet needs within this critical area of healthcare. Through innovative research, development, and advocacy, we aim to make meaningful strides towards improving outcomes and enhancing the quality of life for individuals affected by these debilitating disorders.

Exploring the Significance of Eating Disorders

Eating disorders represent a substantial segment within the healthcare landscape, characterized by profound unmet patient needs. These disorders are not only prevalent but also pose significant health risks, leading to detrimental consequences for individuals and immense burdens on healthcare systems worldwide. Here’s why we focus on eating disorders:

 

  1. Commonality: Eating disorders affect a significant portion of the global population, with an estimated prevalence of 8% [1]. This widespread occurrence highlights the urgent need for effective interventions to address the underlying issues.
  2. Lethality: Among eating disorders, Anorexia Nervosa stands out as one of the most deadly conditions, claiming the lives of approximately 10% of patients [2]. Shockingly, a quarter of these fatalities result from suicide, underscoring the severity of the disorder and the critical need for viable treatment options.
  3. Economic Impact: The financial burden associated with eating disorders is substantial, with Anorexia Nervosa ranking as the most expensive eating disorder to treat, costing approximately USD 11.6 billion annually [2]. This financial strain not only affects individuals and their families but also imposes significant costs on healthcare systems worldwide.

Why Anorexia Nervosa?

Within the spectrum of eating disorders, our focus on Anorexia Nervosa is driven by several compelling factors:

 

  1. High Mortality Rate: Anorexia Nervosa carries the highest mortality rate among eating disorders, making it a critical target for intervention. With up to 10% of patients succumbing to the disorder and a quarter of deaths attributed to suicide, urgent action is needed to address this pressing public health issue.
  2. Lack of Pharmacological Options: Despite the severity of Anorexia Nervosa, there are currently no FDA-approved pharmacological treatments available. This gap in treatment options underscores the urgent need for innovative solutions to improve outcomes for individuals battling this debilitating disorder.
  3. Chronic Nature: Many individuals with Anorexia Nervosa experience chronic, life-long illness, with up to 50% of patients enduring ongoing struggles even after treatment [2]. This chronicity underscores the importance of developing effective interventions that offer sustained relief and support long-term recovery.
17 Hanover Square, London W1S 1BN
info@psych.capital +442038387621